Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to $92000.0.

  • Pharma's Cost of Revenue fell 5700.93% to $92000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $595000.0, marking a year-over-year increase of 1486.49%. This contributed to the annual value of $652000.0 for FY2025, which is 653.59% up from last year.
  • Per Pharma's latest filing, its Cost of Revenue stood at $92000.0 for Q3 2025, which was down 5700.93% from $174000.0 recorded in Q2 2025.
  • Over the past 5 years, Pharma's Cost of Revenue peaked at $300000.0 during Q2 2023, and registered a low of $18000.0 during Q3 2021.
  • For the 5-year period, Pharma's Cost of Revenue averaged around $118789.5, with its median value being $103000.0 (2023).
  • Per our database at Business Quant, Pharma's Cost of Revenue tumbled by 9052.04% in 2021 and then skyrocketed by 32857.14% in 2023.
  • Quarter analysis of 5 years shows Pharma's Cost of Revenue stood at $80000.0 in 2021, then surged by 187.5% to $230000.0 in 2022, then plummeted by 69.13% to $71000.0 in 2023, then soared by 115.49% to $153000.0 in 2024, then tumbled by 39.87% to $92000.0 in 2025.
  • Its last three reported values are $92000.0 in Q3 2025, $174000.0 for Q2 2025, and $176000.0 during Q1 2025.